Pridopidine for Huntington's Disease

(PRECISE-HD Trial)

This trial tests whether the drug pridopidine can slow the progression of Huntington's Disease (HD) over a year. Researchers aim to determine if pridopidine improves everyday tasks, cognitive function, muscle movement, and overall quality of life compared to a placebo (a pill with no active drug). Suitable candidates for this trial are adults diagnosed with HD who have noticeable movement issues and have not taken certain medications in the past six months. Participants will take a capsule twice daily for a year and visit the clinic six times for check-ups. After the first year, all participants will receive pridopidine for an additional two years. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial requires that you have not used certain medications, like antipsychotics, for at least 6 months before starting. It's not encouraged to stop these medications just to join the trial. If you're on medications that prolong the QT interval, you need to stop them 4 weeks before the trial.

Research has shown that pridopidine has been tested in over 1,700 people, with some using it for up to seven years. The findings indicate that it is generally safe and well-tolerated. In a study of 1,067 patients with Huntington's Disease (HD), pridopidine's side effects were similar to those of a placebo, a harmless substance used for comparison. So far, pridopidine has demonstrated a good safety record, with no major safety concerns reported. This suggests that most people can use the treatment without serious problems.¹²³⁴⁵

Pridopidine is unique because it offers a novel approach to treating Huntington's disease by targeting the sigma-1 receptor, which plays a key role in neuroprotection and cellular function. Unlike current treatments, such as tetrabenazine and deutetrabenazine, which primarily focus on managing symptoms like chorea through dopamine depletion, pridopidine aims to preserve and enhance neuronal health. Researchers are excited about pridopidine because it holds the potential not just to alleviate symptoms, but also to modify the underlying disease progression, offering hope for long-term improvement in patients' quality of life.

Research has shown that pridopidine might help treat Huntington's Disease. In this trial, participants will receive either pridopidine or a placebo. Studies have found that pridopidine can slow the disease's progression and improve patients' movement abilities. For example, patients taking pridopidine scored better on a test measuring movement problems. Additionally, pridopidine helped patients maintain daily activities. Most people can take this treatment without serious side effects, indicating it is generally well-tolerated. These findings suggest that pridopidine could help manage symptoms of Huntington's Disease.¹²⁴⁶⁷